Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu 225009, China; Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu 225009, China; Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, Jiangsu 225009, China; Joint International Research Laboratory of Agriculture and Agri-product Safety of the Ministry of Education, Yangzhou University, Yangzhou, Jiangsu 225009, China.
Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu 225009, China; Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu 225009, China; Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, Jiangsu 225009, China; Joint International Research Laboratory of Agriculture and Agri-product Safety of the Ministry of Education, Yangzhou University, Yangzhou, Jiangsu 225009, China.
Vaccine. 2021 Mar 1;39(9):1383-1391. doi: 10.1016/j.vaccine.2021.01.059. Epub 2021 Feb 4.
Live attenuated Salmonellavaccine (LASV) is considered to be an effective contributory measure during the control of Salmonella infection. A Salmonella Pullorum spiC mutant was evaluated comprehensively as a LASV candidate (LASV-p) for broilers in terms of safety and immunogenicity. LASV-p was adminstered to 3-day broilers by intramuscular injection. The LD increased 126 fold, and no tissue lesions were observed in the liver, spleen and cecum, in comparison with the control group inoculated with PBS and a passive group by wild-type Salmonella. Growth rates of all broilers were normal and not affected. LASV-p persisted in vivo until 21 days in liver, 28 days in spleen and 35 days in feces, and induced high levels of humoral IgG and mucosal IgA. Cellular immunity was also stimulated in the form of antigen-specific lymphocyte proliferation and higher counts of CD3CD8 T cells and increased expression of mRNA of Th1 cytokines, IFN-γ and IL-2, in the early stage, and Th2 cytokines, IL-4 and IL-10, in the later stages. LASV-p provided at least 90% immuneprotection against a wild-type Salmonella Pullorum and cross-protection in different degree against other Salmonella searovars. Oral vaccine could also offer high immune protection of 87.5%. These results indicated that LASV-p vaccine candidate had a high level of safety and immune protection and it might be developed as a novel easy-to-use oral vaccine to improve poultry health in the future.
减毒活沙门氏菌疫苗（LASV）被认为是控制沙门氏菌感染的有效辅助措施。一种减毒鸡白痢沙门氏菌 spic 突变株作为 LASV 候选疫苗（LASV-p）在肉鸡安全性和免疫原性方面进行了全面评估。LASV-p 通过肌肉注射接种 3 日龄肉鸡。与接种 PBS 的对照组和野生型沙门氏菌的被动组相比，LD 增加了 126 倍，肝脏、脾脏和盲肠未观察到组织病变。所有肉鸡的生长速度均正常，不受影响。LASV-p 在体内持续存在，肝脏中持续 21 天，脾脏中持续 28 天，粪便中持续 35 天，并诱导高水平的体液 IgG 和黏膜 IgA。细胞免疫也以抗原特异性淋巴细胞增殖和更高的 CD3CD8 T 细胞计数以及 Th1 细胞因子 IFN-γ 和 IL-2 的 mRNA 表达的形式得到刺激，在早期阶段为 Th2 细胞因子 IL-4 和 IL-10。LASV-p 对野生型鸡白痢沙门氏菌提供了至少 90%的免疫保护，对其他沙门氏菌血清型具有不同程度的交叉保护。口服疫苗也能提供 87.5%的高免疫保护。这些结果表明，LASV-p 候选疫苗具有高水平的安全性和免疫保护力，未来可能开发为一种新型、易于使用的口服疫苗，以改善家禽健康。
